

In silico Drug Discovery Workshop

hosted by the NCATS Assay Guidance Manual Program

Wednesday, October 23, 2024 – Thursday, October 24, 2024 ~ Virtual (All times are in ET)

AGENDA: Day 1

		· · · · · · · · · · · · · · · · · · ·
11:00 AM	Introductory Comments Joni Rutter, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Kimberly Sciarretta, Biomedical Advanced Research and Development Authority (BARDA)	
11:20 AM	Overview of Workshop Objectives Sarine Markossian and Alexey Zakharov, NCATS, NIH	
11:30 AM	Keynote: Computer-Aided Drug Discovery Then and Now Martha S. Head (Marti), Amgen Inc.	
12:15 PM	Lunch	
12:45 PM	Session 1: Data sourcing for <i>in silico</i> drug discovery Chair: Sarine Markossian, NCATS 12:45 PM 15 Years of ChEMBL: Challenges & Opportunities Barbara Zdrazil, European Bioinformatics Institute (EMBL-EBI)	
	Paxlov	n Data Bank: From Two Epidemics to the Global Pandemic to mRNA Vaccines and id n K. Burley, Rutgers
1:45 PM	Break	
2:00 PM	Session 2: In silico methodologies used in drug discovery Chair: Alexander Tropsha, University of North Carolina Chapel Hill 2:00 PM Cartography-Guided Exploration of (Ultra)Large Chemical Spaces Alexandre Varnek, The University of Strasbourg	
	2:30 PM Virtual	Screening (TBD) Schneider, ETH Zürich
	3:00 PM Synthe	esis-Aware Library Design and Optimal Experimental Design W. Coley, Massachusetts Institute of Technology (MIT)
	3:30 PM Physic	s-Based Modeling in Drug Discovery . Chodera, Memorial Sloan-Kettering Cancer Center
4:00 PM	Break	
4:15 PM	Session 3: Applications of <i>in silico</i> methodologies in drug discovery Chair: Shyam Rele, BARDA 4:15 PM Applying Artificial Intelligence in a Small Drug Discovery Company Sean Ekins, Collaborations Pharmaceuticals, Inc. The Computational Assay Driven Discovery of a Novel DHODH Inhibitor Series for Malaria Chemoprevention	
		eher, Novartis BioMedical Research



Summary of Day 1 and Adjourn

5:15 PM

AGENDA: Day 2

11:00 AM Session 3: Applications of in silico methodologies in drug discovery (continued)

Chair: Shyam Rele, BARDA

11:00 AM Industrializing Early Drug Discovery at Scale

Marissa Saunders, Recursion Pharmaceuticals

11:30 AM End-to-End Drug Discovery and Development Using Generative Al and Robotics

Alex Zhavoronkov. Insilico Medicine

12:00 PM **Lunch**

12:30 PM Session 4: Emerging trends in in silico drug discovery

Chair: Alexey Zakharov, NCATS

12:30 PM Understanding the Chameleonicity and Permeability of PROTACs Using Molecular

Dynamics Simulations, Markov Models, and Deep Learning

Bryn Taylor, Johnson & Johnson Innovative Medicine

1:00 PM Data Generation in Support of Computational Drug Discovery

Cheryl H Arrowsmith, University of Toronto

1:30 PM Human-Al-Robot Collaboration to Accelerate Materials and Molecular Discovery

Milad Abolhasani, North Carolina State University

2:00 PM Design of New Protein Functions Using Deep Learning

David Baker, University of Washington

2:30 PM Break

3:00 PM Panel Discussion: Bridging the gaps in translation

Chair and moderator: Rommie Amaro, University of California San Diego (USCD)

Panelists: Pat Walters, Relay Therapeutics; Russ B Altman, Stanford University; Joel Karpiak, GSK; Martha S. Head

(Marti), Amgen Inc.

3:00 PM Introduction to the Session and Challenges Ahead

Rommie Amaro, UCSD

3:20 PM Dangers of Poor Data (TBD)

Pat Walters. Relay Therapeutics

3:40 PM Paying Attention to Attention in Al Generative Models

Russ B Altman, Stanford University

4:00 PM Team Environment for Better Translation (TBD)

Joel Karpiak, GSK

4:20 PM Discussion and Q&A

5:00 PM Closing Session: Summary of Discussions and Perspectives on the Challenges Ahead

Alexey Zakharov, NCATS; Alexander Tropsha, UNC Chapel Hill; Rommie Amaro, USCD

5:15 PM Closing Statement and Adjourn